LI-RADS 2018版MRI治疗反应算法:消融后肝细胞癌的评估
本回顾性研究纳入2011年1月至2015年12月单中心消融后行肝移植的36例患者53个病灶,用LI-RADS 2018版治疗反应算法评估消融后肝细胞癌的坏死程度。读者间一致性κ=0.71;将LR-TR不确定视为无活性时敏感度40%-77%、特异度85%-97%,视为有活性时敏感度81%-87%、特异度81%-85%;6个(11%)病灶为LR-TR不确定,其中5个病理为不完全坏死。
要点
- 消融后评估采用LI-RADS 2018版治疗反应算法,LR-TR分类读者间一致性κ=0.71,高于治疗前LI-RADS分类的0.40。
- LR-TR不确定病灶中多数(5/6)病理为不完全坏死,报告时应结合此点解读。
- LR-TR不确定的归类方式(视为有活性或无活性)明显影响敏感度与特异度,需在报告中说明所采用的处理方式。
核心结论
- LI-RADS治疗反应算法可用于预测消融后肝细胞癌有活性或无活性。
- 多数评为治疗反应不确定的消融病灶在组织病理学上为不完全坏死。
研究设计与样本
- 回顾性研究,纳入2011年1月至2015年12月单中心因疑似肝细胞癌接受消融治疗并随后行肝移植的患者36例(平均年龄58岁±5,32例男性),共53个病灶。
- 以移植组织病理学为参考标准,将病灶分为完全坏死(100%)或不完全坏死(≤99%)。
- 3名放射科医师分别用LI-RADS 2018版评估治疗前MRI表现、用治疗反应算法评估治疗后MRI表现。
- 读者间一致性用Fleiss κ检验评估;预测坏死类别的效能采用广义混合效应模型计算,以校正按受试者聚类的效应。
诊断标准与关键数值
- 治疗前LI-RADS分类的读者间一致性κ=0.40(95%CI:0.15,0.67;P<.01),低于治疗反应算法分类的κ=0.71(95%CI:0.59,0.84;P<.01)。
- 将LR-TR不确定评估视为无活性时,各读者预测肿瘤坏死的敏感度为40%至77%,特异度为85%至97%。
- 将LR-TR不确定评估视为有活性时,各读者预测肿瘤坏死的敏感度为81%至87%,特异度为81%至85%。
- 53个治疗病灶中6个(11%)经共识评为LR-TR不确定,其中5个(5/6)在组织病理学上为不完全坏死。
临床应用与阅片要点
- 消融后随访MRI可按LI-RADS 2018版治疗反应算法将病灶归为有活性或无活性,用于预测病理坏死状态。
- 报告LR-TR不确定病灶时应提示其多数为不完全坏死,避免简单判为无活性。
- 解读效能数据时需注意LR-TR不确定的归类方式:视为无活性时敏感度偏低(40%至77%),视为有活性时敏感度升高(81%至87%)但特异度略降(81%至85%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background The Liver Imaging Reporting and Data System (LI-RADS) treatment response algorithm (TRA) is used to assess presumed hepatocellular carcinoma (HCC) after local-regional therapy, but its performance has not been extensively assessed. Purpose To assess the performance of LI-RADS version 2018 TRA in the evaluation of HCC after ablation. Materials and Methods In this retrospective study, patients who underwent ablation therapy for presumed HCC followed by liver transplantation between January 2011 and December 2015 at a single tertiary care center were identified. Lesions were categorized as completely (100%) or incompletely (≤99%) necrotic based on transplant histology. Three radiologists assessed pre- and posttreatment MRI findings using LI-RADS version 2018 and the TRA, respectively. Interreader agreement was assessed by using the Fleiss κ test. Performance characteristics for predicting necrosis category based on LI-RADS treatment response (LR-TR) category (viable or nonviable) were calculated by using generalized mixed-effects models to account for clustering by subject. Results A total of 36 patients (mean age, 58 years ± 5 [standard deviation]; 32 men) with 53 lesions was included. Interreader agreement for pretreatment LI-RADS category was 0.40 (95% confidence interval [CI]: 0.15, 0.67; P < .01) and was lower than the interreader agreement for TRA category (κ = 0.71; 95% CI: 0.59, 0.84; P < .01). After accounting for clustering by subject, sensitivity of tumor necrosis across readers ranged from 40% to 77%, and specificity ranged from 85% to 97% when LR-TR equivocal assessments were treated as nonviable. When LR-TR equivocal assessments were treated as viable, sensitivity of tumor necrosis across readers ranged from 81% to 87%, and specificity ranged from 81% to 85% across readers. Six (11%) of 53 treated lesions were LR-TR equivocal by consensus, with most (five of six) incompletely necrotic at histopathology. Conclusion The Liver Imaging Reporting and Data System treatment response algorithm can be used to predict viable or nonviable hepatocellular carcinoma after ablation. Most ablated lesions rated as treatment response equivocal were incompletely necrotic at histopathology. © RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Do and Mendiratta-Lala in this issue.
引用
- Chaudhry M, McGinty KA, Mervak B, et al. The LI-RADS Version 2018 MRI Treatment Response Algorithm: Evaluation of Ablated Hepatocellular Carcinoma. Radiology. 2019. PMID: 31845843. doi:10.1148/radiol.2019191581
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。